| ||||||||||||||
|
|
|||||||||||||



*Allegheny General Hospital, Pittsburgh, Pennsylvania;
MCP-Hahnemann University, Philadelphia, Pennsylvania;
Duke University Medical Center, Durham, North Carolina;
Albany Medical Center, Albany, New York; ||||St. Johns Hospital, Springfield, Illinois; ¶St. Francis Hospital, Milwaukee, Wisconsin; and #IBEX Technologies, Montreal, Quebec, Canada
Address correspondence to Jay Charles Horrow, MD, MCP-Hahnemann University, 245 N. 15th St., MS 310, Philadelphia, PA 19102. Address e-mail to horrow{at}drexel.edu
Heparinase-I, a specific heparin-degrading enzyme, may represent an alternative to protamine. We explored the dose of heparinase-I for efficacy and safety in patients undergoing coronary artery surgery. At the conclusion of cardiopulmonary bypass, subjects received 5, 7, or 10 µg/kg of open-label heparinase-I instead of protamine. Activated clotting time (ACT) and its difference from a contemporaneous heparin-free sample (
ACT) at 3 min before and 3, 6, and 9 min after heparinase-I determined reversal efficacy. After surgery, we recorded hourly chest tube drainage. Systemic and pulmonary arterial blood pressure and cardiac output measurements before and immediately after heparinase-I were used to evaluate hemodynamic safety. Coagulation measurements included anti-factor Xa and anti-factor IIa activities. Forty-nine patients from seven institutions participated: 12 received 5 µg/kg, 21 received 7 µg/kg, 4 received two doses of 7 µg/kg, 8 received 10 µg/kg, and 4 received two doses of 10 µg/kg. Treatment groups did not differ demographically. Median
ACT 9 min later was 11, 7, and 4 s for the 5, 7, and 10 µg/kg groups, respectively. No adverse hemodynamic changes occurred with heparinase-I administration. The authors conclude that heparinase-I effectively restored the ACT after cardiopulmonary bypass. This effect appeared to be dose dependent.
IMPLICATIONS: Heparinase-I (NeutralaseTM) successfully restored activated coagulation time with no adverse hemodynamic events in patients undergoing coronary artery surgery with cardiopulmonary bypass in an open-label dose-determining trial.
This article has been cited by other articles:
![]() |
H. U. Jones, J. B. Muhlestein, K. W. Jones, D. G. Renlund, T. L. Bair, T. J. Bunch, B. D. Horne, D. L. Lappe, J. L. Anderson, and D. B. Doty Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated with Increased Surgical Re-Exploration for Bleeding Ann. Thorac. Surg., August 1, 2005; 80(2): 518 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Butterworth, Y. A. Lin, R. C. Prielipp, J. Bennett, J. W. Hammon, and R. L. James Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass Ann. Thorac. Surg., November 1, 2002; 74(5): 1589 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Roth and J. Horrow Can You Reheparinize After Heparinase-I? * Response Anesth. Analg., August 1, 2002; 95(2): 501 - 501. [Full Text] [PDF] |
||||
|